Previous Close | 191,500.00 |
Open | 193,300.00 |
Bid | 187,300.00 x 0 |
Ask | 187,400.00 x 0 |
Day's Range | 184,700.00 - 193,500.00 |
52 Week Range | 131,000.00 - 241,000.00 |
Volume | |
Avg. Volume | 658,962 |
Market Cap | 38.681T |
Beta (5Y Monthly) | 0.31 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 500.00 (0.26%) |
Ex-Dividend Date | Dec 27, 2023 |
1y Target Est | N/A |
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
South Korea's Celltrion Healthcare has launched a copycat version to AbbVie Inc's Humira at about a 5% discount, adding to the growing competition for the blockbuster rheumatoid arthritis drug in the U.S. The biosimilar, Yuflyma, became available for sale in the U.S. on Sunday, the company said a day later. Yuflyma is listed at $6,576.50 per month compared to the current list price of Humira at $6,922 per carton and is available in two device types — auto-injector and pre-filled syringe options.